Available online 14 January 2023, 107524

Inflammation, cardiomyocyte injury and microvascular thrombosis are increased in the atria of the heart in COVID-19 patients.

The increased inflammation and thrombogenicity are found both in the atrial myocardium and adipose tissue.

In contrast to previous observations in the ventricles, the cardiac pathology of the atria remains high also in second wave COVID-19 patients.

. Histopathological studies have shown inflammation, cardiomyocyte injury and microvascular thrombosis in the ventricular myocardium of patients with coronavirus disease 2019 (COVID-19). However, although atrial dysfunction is common in COVID-19, little is known about histopathological changes in the atria of the heart. We therefore analyzed inflammation, cardiomyocyte injury and microvascular thrombogenicity in the atria of deceased patients with COVID-19.

. Atrial tissue was obtained from autopsied COVID-19 (n=16) patients and control patients (n=10) and analyzed using immunohistochemistry. The infiltration of CD45+ leukocytes, CD3+ T lymphocytes, CD68+ macrophages, MPO+ neutrophils and Tryptase+ mast cells were quantified as well as cardiomyocyte damage and microvascular thrombosis. In addition, Tissue Factor (TF) and Factor XII (FXII) were quantified as markers of microvascular thrombogenicity.

. The numbers of lymphocytes, macrophages and neutrophils were significantly increased in the atrial myocardium and epicardial atrial adipose tissue of COVID-19 patients compared with the control group. This was accompanied by dispersed cardiomyocyte injury, the occasional presence of microvascular thrombosis and an increased presence of TF and FXII in the microvascular endothelium.

. Severe COVID-19 induces inflammation, cardiomyocyte injury and microvascular thrombosis in the atria of the heart.

First and second wave COVID-19

Atria

Inflammation

Thrombi

Coagulation factors

© 2023 The Author(s). Published by Elsevier Inc.